A Phase 3 interventional study of Evolocumab and Ezetimibe in Hyperlipidemia, sponsored by Amgen. Completed at 83 sites in 10 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-11-08.
Sponsored by Amgen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing evolocumab in Hyperlipidemias — none open to participants now, none under way, none of them phase 3. evolocumab · Hyperlipidemias.
Among the 21 studies testing evolocumab in Hyperlipidemias, this one is the 5th largest by enrollment, is one of 7 that started in 2013, is one of 12 in phase 3, and was the 5th registered.
862 studies on the registry are indexed under Hyperlipidemias; 109 are open to participants now.
Browse Hyperlipidemias studies →None of the 21 studies testing evolocumab in Hyperlipidemias is open now. The open studies under Hyperlipidemias, anywhere →
evolocumab: first FDA approval 2015 (REPATHA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 67 Hyperlipidemias studies recruiting now, 27 (40%) set no upper age limit and 32 (48%) stop at 75 or younger; 8 take children under 18; 16 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 7 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 615 is above the median of 88 across 735 interventional studies indexed under Hyperlipidemias.
Median enrollment 307 across the 21 interventional studies. Of the 20 that completed or were terminated, 19 (95%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 21 have an industry lead sponsor. The 6 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
17 studies in Hyperlipidemias by Amgen: none open now, none under way, none of them phase 3. Of 17 finished, 17 (100%) have results posted.
Among the 17 studies in Hyperlipidemias by Amgen, this one is the 5th largest by enrollment, is one of 7 that started in 2013, is one of 11 in phase 3, and was the 5th registered.
Amgen’s Hyperlipidemias studies by the year they started, since 2010.
None of the studies under way reaches primary completion within a year.
Among the 21 studies testing evolocumab in Hyperlipidemias, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Amgen’s 17 in Hyperlipidemias:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective was to evaluate the effect of 12 weeks of evolocumab subcutaneous (SC) monotherapy every 2 weeks (Q2W) and monthly (QM), compared with placebo and ezetimibe, on percent change from baseline in low-density lipoprotein cholesterol (LDL-C) in adults with a 10-year Framingham risk score of 10% or less.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received placebo subcutaneous injection once every 2 weeks (Q2W) and placebo tablets once a day for up to 12 weeks.
Biological: Placebo to Evolocumab · Other: Placebo to Ezetimibe
Participants received placebo subcutaneous injection once every month (QM) and placebo tablets once a day for up to 12 weeks.
Biological: Placebo to Evolocumab · Other: Placebo to Ezetimibe
Participants received placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once a day for up to 12 weeks.
Drug: Ezetimibe · Biological: Placebo to Evolocumab
Participants received placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for up to 12 weeks.
Drug: Ezetimibe · Biological: Placebo to Evolocumab
Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.
Biological: Evolocumab · Other: Placebo to Ezetimibe
Participants received 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once a day for up to 12 weeks.
Biological: Evolocumab · Other: Placebo to Ezetimibe
Administered by subcutaneous injection
Also known as: AMG 145, Repatha
Administered orally once a day
Also known as: Zetia
Administered by subcutaneous injection
Administered orally once daily
Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 12
Time frame: Baseline and Week 12
Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12
Time frame: Baseline and Weeks 10 and 12
Change From Baseline in LDL-C at the Mean of Weeks 10 and 12
Time frame: Baseline and Weeks 10 and 12
Change From Baseline in LDL-C at Week 12
Time frame: Baseline and Week 12
Percentage of Participants Who Achieved a Mean LDL-C at Weeks 10 and 12 of Less Than 70 mg/dL
Time frame: Weeks 10 and 12
Percentage of Participants Who Achieved LDL-C < 70 mg/dL at Week 12
Time frame: Week 12
Percent Change From Baseline in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) at the Mean of Weeks 10 and 12
Time frame: Baseline and Weeks 10 and 12
Percent Change From Baseline in Non-HDL-C at Week 12
Time frame: Baseline and Week 12
Percent Change From Baseline in Apolipoprotein B at the Mean of Weeks 10 and 12
Time frame: Baseline and Weeks 10 and 12
Percent Change From Baseline in Apolipoprotein B at Week 12
Time frame: Baseline and Week 12
Percent Change From Baseline in Total Cholesterol/High Density Lipoprotein-cholesterol Ratio at the Mean of Weeks 10 and 12
Time frame: Baseline and Weeks 10 and 12
Percent Change From Baseline in Total Cholesterol/High Density Lipoprotein-cholesterol Ratio at Week 12
Time frame: Baseline and Week 12
Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at the Mean of Weeks 10 and 12
Time frame: Baseline and Weeks 10 and 12
Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at Week 12
Time frame: Baseline and Week 12
Percent Change From Baseline in Lipoprotein (a) at the Mean of Weeks 10 and 12
Time frame: Baseline and Weeks 10 and 12
Percent Change From Baseline in Lipoprotein (a) at Week 12
Time frame: Baseline and Week 12
Percent Change From Baseline in Triglycerides at the Mean of Weeks 10 and 12
Time frame: Baseline and Weeks 10 and 12
Percent Change From Baseline in Triglycerides at Week 12
Time frame: Baseline and Week 12
Percent Change From Baseline in Very Low Density Lipoprotein Cholesterol (VLDL-C) at the Mean of Weeks 10 and 12
Time frame: Baseline and Weeks 10 and 12
Percent Change From Baseline in VLDL-C at Week 12
Time frame: Baseline and Week 12
Percent Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C) at the Mean of Weeks 10 and 12
Time frame: Baseline and Weeks 10 and 12
Percent Change From Baseline in HDL-C at Week 12
Time frame: Baseline and Week 12
Men and women ≥ 18 to ≤ 80 years of age with fasting low-density lipoprotein cholesterol (LDL-C) ≥ 100 mg/dL and \< 190 mg/dL and fasting triglycerides ≤ 400 mg/dL with a 10-year Framingham Risk Score of 10% or less were eligible for this study. The first participant was enrolled on 21 January 2013 and the last participant was enrolled 29 July 2013.
| Milestone | Placebo Q2W | Placebo QM | Ezetimibe (Q2W) | Ezetimibe (QM) | Evolocumab Q2W | Evolocumab QM |
|---|---|---|---|---|---|---|
| Started | 77 | 78 | 77 | 77 | 153 | 153 |
| Received at least 1 dose of study drug | 76 | 78 | 77 | 77 | 153 | 153 |
| Completed | 74 | 77 | 73 | 76 | 147 | 151 |
| Not completed | 3 | 1 | 4 | 1 | 6 | 2 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 | 0 | 2 | 0 |
| Withdrew: Decision by sponsor | 2 | 0 | 3 | 0 | 2 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 | 1 | 1 | 2 | 1 |
| percent change | Placebo Q2W | Placebo QM | Ezetimibe (Q2W) | Ezetimibe (QM) | Evolocumab Q2W | Evolocumab QM |
|---|---|---|---|---|---|---|
| Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 12 | 0.10 ± 1.67 | -1.34 ± 1.54 | -17.75 ± 1.67 | -18.57 ± 1.56 | -57.04 ± 1.23 | -56.12 ± 1.12 |
| percent change | Placebo Q2W | Placebo QM | Ezetimibe (Q2W) | Ezetimibe (QM) | Evolocumab Q2W | Evolocumab QM |
|---|---|---|---|---|---|---|
| Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12 | -0.43 ± 1.45 | -1.41 ± 1.37 | -17.52 ± 1.46 | -19.12 ± 1.39 | -56.93 ± 1.07 | -58.81 ± 1.00 |
| mg/dL | Placebo Q2W | Placebo QM | Ezetimibe (Q2W) | Ezetimibe (QM) | Evolocumab Q2W | Evolocumab QM |
|---|---|---|---|---|---|---|
| Change From Baseline in LDL-C at the Mean of Weeks 10 and 12 | 1.2 ± 2.3 | 0.0 ± 2.1 | -23.1 ± 2.3 | -25.9 ± 2.1 | -78.4 ± 1.7 | -81.9 ± 1.5 |
| mg/dL | Placebo Q2W | Placebo QM | Ezetimibe (Q2W) | Ezetimibe (QM) | Evolocumab Q2W | Evolocumab QM |
|---|---|---|---|---|---|---|
| Change From Baseline in LDL-C at Week 12 | 1.9 ± 2.5 | -0.1 ± 2.4 | -23.4 ± 2.5 | -25.0 ± 2.4 | -78.4 ± 1.9 | -77.9 ± 1.7 |
| percentage of participants | Placebo Q2W | Placebo QM | Ezetimibe (Q2W) | Ezetimibe (QM) | Evolocumab Q2W | Evolocumab QM |
|---|---|---|---|---|---|---|
| Percentage of Participants Who Achieved a Mean LDL-C at Weeks 10 and 12 of Less Than 70 mg/dL | 0.0 (0.0 to 4.8) | 0.0 (0.0 to 4.9) | 1.3 (0.2 to 7.2) | 2.8 (0.8 to 9.6) | 73.6 (65.7 to 80.2) | 71.3 (63.6 to 78.0) |
| percentage of participants | Placebo Q2W | Placebo QM | Ezetimibe (Q2W) | Ezetimibe (QM) | Evolocumab Q2W | Evolocumab QM |
|---|---|---|---|---|---|---|
| Percentage of Participants Who Achieved LDL-C < 70 mg/dL at Week 12 | 1.4 (0.3 to 7.8) | 0.0 (0.0 to 5.2) | 1.4 (0.3 to 7.7) | 1.4 (0.3 to 7.8) | 72.9 (64.8 to 79.8) | 65.4 (57.1 to 72.9) |
| percent change | Placebo Q2W | Placebo QM | Ezetimibe (Q2W) | Ezetimibe (QM) | Evolocumab Q2W | Evolocumab QM |
|---|---|---|---|---|---|---|
| Percent Change From Baseline in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) at the Mean of Weeks 10 and 12 | -1.41 ± 1.34 | 1.32 ± 1.24 | -14.64 ± 1.35 | -16.48 ± 1.25 | -50.22 ± 0.99 | -51.96 ± 0.90 |
| percent change | Placebo Q2W | Placebo QM | Ezetimibe (Q2W) | Ezetimibe (QM) | Evolocumab Q2W | Evolocumab QM |
|---|---|---|---|---|---|---|
| Percent Change From Baseline in Non-HDL-C at Week 12 | -0.31 ± 1.48 | 1.51 ± 1.38 | -14.89 ± 1.47 | -16.48 ± 1.39 | -50.12 ± 1.08 | -49.68 ± 1.01 |
| percent change | Placebo Q2W | Placebo QM | Ezetimibe (Q2W) | Ezetimibe (QM) | Evolocumab Q2W | Evolocumab QM |
|---|---|---|---|---|---|---|
| Percent Change From Baseline in Apolipoprotein B at the Mean of Weeks 10 and 12 | 0.05 ± 1.51 | 1.54 ± 1.41 | -13.47 ± 1.52 | -14.75 ± 1.43 | -47.04 ± 1.12 | -49.39 ± 1.03 |
| percent change | Placebo Q2W | Placebo QM | Ezetimibe (Q2W) | Ezetimibe (QM) | Evolocumab Q2W | Evolocumab QM |
|---|---|---|---|---|---|---|
| Percent Change From Baseline in Apolipoprotein B at Week 12 | 0.59 ± 1.58 | 1.84 ± 1.53 | -13.17 ± 1.58 | -14.02 ± 1.54 | -47.21 ± 1.17 | -46.59 ± 1.12 |
| percent change | Placebo Q2W | Placebo QM | Ezetimibe (Q2W) | Ezetimibe (QM) | Evolocumab Q2W | Evolocumab QM |
|---|---|---|---|---|---|---|
| Percent Change From Baseline in Total Cholesterol/High Density Lipoprotein-cholesterol Ratio at the Mean of Weeks 10 and 12 | 0.44 ± 1.29 | 6.42 ± 1.50 | -9.14 ± 1.29 | -11.90 ± 1.51 | -38.49 ± 0.95 | -39.41 ± 1.08 |
| percent change | Placebo Q2W | Placebo QM | Ezetimibe (Q2W) | Ezetimibe (QM) | Evolocumab Q2W | Evolocumab QM |
|---|---|---|---|---|---|---|
| Percent Change From Baseline in Total Cholesterol/High Density Lipoprotein-cholesterol Ratio at Week 12 | 1.18 ± 1.39 | 7.02 ± 1.67 | -10.03 ± 1.39 | -12.34 ± 1.68 | -38.45 ± 1.02 | -37.65 ± 1.21 |
| percent change | Placebo Q2W | Placebo QM | Ezetimibe (Q2W) | Ezetimibe (QM) | Evolocumab Q2W | Evolocumab QM |
|---|---|---|---|---|---|---|
| Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at the Mean of Weeks 10 and 12 | 1.01 ± 1.69 | 3.85 ± 1.77 | -13.39 ± 1.69 | -14.49 ± 1.79 | -48.12 ± 1.25 | -51.10 ± 1.29 |
| percent change | Placebo Q2W | Placebo QM | Ezetimibe (Q2W) | Ezetimibe (QM) | Evolocumab Q2W | Evolocumab QM |
|---|---|---|---|---|---|---|
| Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at Week 12 | 1.12 ± 1.77 | 4.51 ± 1.90 | -12.69 ± 1.77 | -14.29 ± 1.92 | -48.45 ± 1.31 | -48.26 ± 1.39 |
| percent change | Placebo Q2W | Placebo QM | Ezetimibe (Q2W) | Ezetimibe (QM) | Evolocumab Q2W | Evolocumab QM |
|---|---|---|---|---|---|---|
| Percent Change From Baseline in Lipoprotein (a) at the Mean of Weeks 10 and 12 | 0.12 ± 2.72 | 0.00 ± 2.96 | 0.00 ± 2.72 | -2.08 ± 3.01 | -18.37 ± 2.02 | -19.24 ± 2.17 |
| percent change | Placebo Q2W | Placebo QM | Ezetimibe (Q2W) | Ezetimibe (QM) | Evolocumab Q2W | Evolocumab QM |
|---|---|---|---|---|---|---|
| Percent Change From Baseline in Lipoprotein (a) at Week 12 | 0.00 ± 2.75 | 0.00 ± 3.26 | 0.00 ± 2.75 | -2.05 ± 3.28 | -20.41 ± 2.04 | -17.82 ± 2.39 |
| percent change | Placebo Q2W | Placebo QM | Ezetimibe (Q2W) | Ezetimibe (QM) | Evolocumab Q2W | Evolocumab QM |
|---|---|---|---|---|---|---|
| Percent Change From Baseline in Triglycerides at the Mean of Weeks 10 and 12 | -3.89 ± 3.64 | 4.89 ± 4.02 | -1.46 ± 3.60 | -3.97 ± 4.04 | -9.16 ± 2.65 | -15.71 ± 2.92 |
| percent change | Placebo Q2W | Placebo QM | Ezetimibe (Q2W) | Ezetimibe (QM) | Evolocumab Q2W | Evolocumab QM |
|---|---|---|---|---|---|---|
| Percent Change From Baseline in Triglycerides at Week 12 | -1.91 ± 3.13 | 2.01 ± 3.86 | 0.00 ± 3.15 | -2.41 ± 3.89 | -8.14 ± 2.31 | -15.64 ± 2.78 |
| percent change | Placebo Q2W | Placebo QM | Ezetimibe (Q2W) | Ezetimibe (QM) | Evolocumab Q2W | Evolocumab QM |
|---|---|---|---|---|---|---|
| Percent Change From Baseline in Very Low Density Lipoprotein Cholesterol (VLDL-C) at the Mean of Weeks 10 and 12 | -3.81 ± 3.09 | 4.22 ± 3.70 | -2.69 ± 3.12 | -3.33 ± 3.69 | -8.40 ± 2.28 | -16.17 ± 2.65 |
| percent change | Placebo Q2W | Placebo QM | Ezetimibe (Q2W) | Ezetimibe (QM) | Evolocumab Q2W | Evolocumab QM |
|---|---|---|---|---|---|---|
| Percent Change From Baseline in VLDL-C at Week 12 | -1.58 ± 3.67 | 0.00 ± 3.93 | -0.94 ± 3.65 | -3.61 ± 3.87 | -9.52 ± 2.64 | -16.33 ± 2.80 |
| percent change | Placebo Q2W | Placebo QM | Ezetimibe (Q2W) | Ezetimibe (QM) | Evolocumab Q2W | Evolocumab QM |
|---|---|---|---|---|---|---|
| Percent Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C) at the Mean of Weeks 10 and 12 | -1.64 ± 1.26 | -4.67 ± 1.32 | -0.92 ± 1.27 | 0.00 ± 1.33 | 3.89 ± 0.93 | 3.81 ± 0.95 |
| percent change | Placebo Q2W | Placebo QM | Ezetimibe (Q2W) | Ezetimibe (QM) | Evolocumab Q2W | Evolocumab QM |
|---|---|---|---|---|---|---|
| Percent Change From Baseline in HDL-C at Week 12 | -1.15 ± 1.43 | -5.27 ± 1.40 | -2.79 ± 1.42 | -1.47 ± 1.41 | 4.76 ± 1.05 | 4.06 ± 1.01 |
Collected over From the first dose of blinded investigational product until the end of the study (up to 14 weeks).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo Q2W | — | 0/76 (0%) | 9/76 (11.8%) |
| Placebo QM | — | 1/78 (1.3%) | 4/78 (5.1%) |
| Ezetimibe (Q2W) | — | 0/77 (0%) | 10/77 (13%) |
| Ezetimibe (QM) | — | 1/77 (1.3%) | 4/77 (5.2%) |
| Evolocumab Q2W | — | 3/153 (2%) | 12/153 (7.8%) |
| Evolocumab QM | — | 1/153 (0.7%) | 12/153 (7.8%) |
| Event | Placebo Q2W | Placebo QM | Ezetimibe (Q2W) | Ezetimibe (QM) | Evolocumab Q2W | Evolocumab QM |
|---|---|---|---|---|---|---|
| Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/76 | 0/78 | 0/77 | 1/77 | 0/153 | 0/153 |
| Bladder cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/76 | 1/78 | 0/77 | 0/77 | 0/153 | 0/153 |
| Pancreatitis acuteGastrointestinal disorders | 0/76 | 0/78 | 0/77 | 0/77 | 0/153 | 1/153 |
| Upper limb fractureInjury, poisoning and procedural complications | 0/76 | 0/78 | 0/77 | 0/77 | 1/153 | 0/153 |
| Hepatic enzyme increasedInvestigations | 0/76 | 0/78 | 0/77 | 0/77 | 1/153 | 0/153 |
| Renal cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/76 | 0/78 | 0/77 | 0/77 | 1/153 | 0/153 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 0/76 | 0/78 | 0/77 | 0/77 | 1/153 | 0/153 |
| Event | Placebo Q2W | Placebo QM | Ezetimibe (Q2W) | Ezetimibe (QM) | Evolocumab Q2W | Evolocumab QM |
|---|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 5/76 | 1/78 | 2/77 | 1/77 | 4/153 | 5/153 |
| NasopharyngitisInfections and infestations | 1/76 | 2/78 | 4/77 | 2/77 | 3/153 | 3/153 |
| HeadacheNervous system disorders | 3/76 | 1/78 | 4/77 | 1/77 | 5/153 | 5/153 |
| Age, Continuous(years) | Placebo Q2W | Placebo QM | Ezetimibe (Q2W) | Ezetimibe (QM) | Evolocumab Q2W | Evolocumab QM | Total |
|---|---|---|---|---|---|---|---|
| Mean | 54.4 ± 10.3 | 52.6 ± 10.7 | 53.9 ± 11.3 | 53.0 ± 12.7 | 52.5 ± 13.7 | 52.9 ± 12.1 | 53.1 ± 12.1 |
| Sex: Female, Male(Participants) | Placebo Q2W | Placebo QM | Ezetimibe (Q2W) | Ezetimibe (QM) | Evolocumab Q2W | Evolocumab QM | Total |
|---|---|---|---|---|---|---|---|
| Female | 49 | 47 | 53 | 52 | 104 | 101 | 406 |
| Male | 28 | 31 | 24 | 25 | 49 | 52 | 209 |
| Race/Ethnicity, Customized(participants) | Placebo Q2W | Placebo QM | Ezetimibe (Q2W) | Ezetimibe (QM) | Evolocumab Q2W | Evolocumab QM | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 1 | 0 | 2 | 3 |
| Asian | 9 | 8 | 7 | 10 | 12 | 12 | 58 |
| Black or African American | 4 | 6 | 6 | 6 | 9 | 9 | 40 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| White | 64 | 63 | 63 | 60 | 132 | 129 | 511 |
| Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Mixed Race | 0 | 0 | 1 | 0 | 0 | 1 | 2 |
| Race/Ethnicity, Customized(participants) | Placebo Q2W | Placebo QM | Ezetimibe (Q2W) | Ezetimibe (QM) | Evolocumab Q2W | Evolocumab QM | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 6 | 8 | 9 | 11 | 14 | 21 | 69 |
| Not Hispanic or Latino | 71 | 70 | 68 | 66 | 139 | 132 | 546 |
| Stratification Factor: Low-density Lipoprotein Cholesterol (LDL-C)(participants) | Placebo Q2W | Placebo QM | Ezetimibe (Q2W) | Ezetimibe (QM) | Evolocumab Q2W | Evolocumab QM | Total |
|---|---|---|---|---|---|---|---|
| < 130 mg/dL | 23 | 24 | 22 | 22 | 45 | 45 | 181 |
| ≥ 130 mg/dL | 54 | 54 | 55 | 55 | 108 | 108 | 434 |
| LDL-C Concentration(mg/dL) | Placebo Q2W | Placebo QM | Ezetimibe (Q2W) | Ezetimibe (QM) | Evolocumab Q2W | Evolocumab QM | Total |
|---|---|---|---|---|---|---|---|
| Mean | 139.5 ± 21.3 | 144.3 ± 23.9 | 143.3 ± 23.8 | 143.5 ± 23.1 | 141.7 ± 22.3 | 144.4 ± 23.3 | 142.9 ± 22.9 |
| Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) Concentration(mg/dL) | Placebo Q2W | Placebo QM | Ezetimibe (Q2W) | Ezetimibe (QM) | Evolocumab Q2W | Evolocumab QM | Total |
|---|---|---|---|---|---|---|---|
| Mean | 167.4 ± 25.8 | 172.8 ± 31.0 | 168.8 ± 28.9 | 169.4 ± 27.3 | 166.5 ± 25.6 | 170.4 ± 26.6 | 169.0 ± 27.2 |
| Apolipoprotein B Concentration(mg/dL) | Placebo Q2W | Placebo QM | Ezetimibe (Q2W) | Ezetimibe (QM) | Evolocumab Q2W | Evolocumab QM | Total |
|---|---|---|---|---|---|---|---|
| Mean | 103.7 ± 16.8 | 107.3 ± 19.9 | 107.2 ± 19.7 | 106.2 ± 17.8 | 104.5 ± 17.2 | 108.3 ± 17.9 | 106.2 ± 18.1 |
6 further baseline measures are reported on the registry.
Ran from Jan 2013 to primary completion in Oct 2013, 8 months.
Results were first posted in Dec 2015, 2 years 2 months after primary completion. A results delay was requested in May 2014.
Of 51 industry-sponsored phase 3 interventional studies under Hyperlipidemias, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 8 months is below that.
Counting every sponsor, half of 57 studies reached it within 18 months; a quarter within 11 and three quarters within 32.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Evolocumab